Teva Pharmaceuticals has launched a voluntary review of 2 products used to heal the highest blood pressure, because even more medicines face fears on the pretext of the likely risk of cancer.

In a statement from Teva wrote the food and drug review covers all lots of combined pills with amlodipine and valsartan substances and other combined product with amlodipine, valsartan and hydrochlorothiazide.

Substances have every chance of keeping impurities called N-Nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen, the FDA said.

Patients taking or medication must be confused by their doctor or pharmacist for advice or other treatments. Stopping the method of medicines immediately without any comparable candidate has the opportunity to present a significant risk to the well-being of patients, Teva said.

More: Would you like more of this news? Subscribe to the daily briefing in your Inbox.

Buyers and people with issues have all chances to be confused with Teva for a telephone 888-838-2872 or electric mail druginfo@tevapharm.com.

In August, the FDA announced an extended review of valsartan, due to the fact that the products have all chances to keep impurities. Last month it was announced 2 review: time for a product Irbesartan and 2 review for pills losartan potassium hydrochlorothiazide.

During an interview in November with USA TODAY, FDA Commissioner Scott Gottlieb said that the review of medicines for blood pressure displays an overestimated concern for the quality of medicines in order to ensure the inaccessibility of impurities.